the aid library

Filter

819

Routine sterile glove and instrument change at the time of abdominal wound closure to prevent surgical site infection (ChEETAh): a pragmatic, cluster-randomised trial in seven low-income and middle-in

NIHR Global Reserach Health Unit on Global Surgery (2022) CC

The Lancet Vol.400 (2022) p.17-67-1776. Published:October 31, 2022DOI:https://doi.org/10.1016/S0140-6736(22)01884-0. Surgical site infection (SSI) is the most common complication of surgery around the world: ChEETAh trial finds routinely changing gloves and instruments for wound closure could preve ... more

Community Engagement During Public Health Emergencies Like COVID-19: An Action Framework and Toolkit

Bangladesh Red Crescent Society; BRAC; Government of Bangladesh; UN Children's Fund UNICEF; UN Women; World Health Organization WHO (2023) CC

This handbook offers a simple framework of action for actors in local government, and in particular, health leaders such as Civil Surgeons (CSs) and Upazila Health and Family Planning Officers (UHFPQOs), to take ownership and leadership to combat COVID-19 at each district and upazila respectively, w ... more

Download

View PDF

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Democratic Republic of Timor-Leste Ministry of Health - Comprehensive TB Guidelines for National Tuberculosis Program, V Edition

Government of Timor-Leste; World Health Organization (2023) CC

The Democratic Republic of Timor-Leste has the highest TB incidence rate in the South East Asian Region - 498 per 100,000, which is the seventh highest in the world. In Timor-Leste TB is the eighth most common cause of death. The salient observations are as follows: In 2018, 487 (12.5%) of the ... more

Download

View PDF

Lao People’s Democratic Republic-WHO Country Cooperation Strategy 2024–2028

World Health Organization WHO (2023) C_WHO

This country cooperation strategy (CCS) outlines how the World Health Organization (WHO) will work with the Lao People’s Democratic Republic over the next five years (2024–2028), supporting the implementation of the five-year health sector development plans and the Health Sector Reform Strategy ... 2021–2030 to attain the Sustainable Development Goals (SDGs) by 2030. The Lao People’s Democratic Republic experienced substantial economic growth in the 30 years prior to the coronavirus disease (COVID-19) pandemic, contributing to reduced poverty and significant progress toward the SDGs. However, the COVID-19 pandemic brought this development to a halt. It was anticipated that the COVID-19 recovery and the tremendous population growth in recent years would provide opportunities for a shift toward more sustainable and inclusive development in the years ahead. In 2023, however, the contrary was the case. Rural residents, including many ethnic minorities, continued to face marginalization because of limited access to education, health care and economic opportunities. Despite the challenges of COVID-19 and other disease outbreaks, the country has made significant improvements in health. Nonetheless, progress has been uneven and not everyone has benefited from these achievements. In the mountainous region, many people lack access to quality health care because of the unequal distribution of well-trained health-care workers. Preventable deaths due to poor-quality health care for children and newborns, infants and mothers remain a concern, as do communicable diseases such as sexually transmitted infections and tuberculosis. The increasing burden of noncommunicable diseases and the health impact of worsening climate change further heighten the need for strengthened and resilient health systems, which are at risk due to an underfunded health sector and weak economy. This CCS aims to address remaining and future challenges as well as health needs while creating an impact that is sustainable. It identifies three strategic priorities and nine deliverables (Table 1) to support the attainment of the national vision of Health for all by all, as articulated in the 9th Health Sector Development Plan 2021–2025. It contributes to the country’s goals to achieve universal health coverage, graduate from least developed country status by 2026 and attain SDGs by 2030. more

Download

View PDF

Surgical site infection prevention recommendations: Preoperative Period

World Health Organization WHO (2018) C_WHO

Download

View PDF

Surgical site infection prevention recommendations. Postoperative Period

World Health Organization WHO (2018) C_WHO

Download

View PDF

Venezuela: COVID-19 - Flash Update Nº 2

OCHA; Reliefweb OCHA; Reliefweb (2020) C2

02 de abril de 2020

Medios auxiliares para el diagnóstico microscópico del paludismo

World Health Organization WHO (2010) C_WHO

Organización Mundial de la Salud. (‎2011)‎. Medios auxiliares para el diagnóstico microscópico del paludismo.

External Link

Una Nueva Esperanza Para Pacientes Con Leishmaniasis

Drugs for Neglected Diseases initiative DNDi (2022) CC

La leishmaniasis es una enfermedad tropical desatendida sensible al clima, trasmitida por la picadura de insectos flebótomos y se calcula que amenaza a mil millones de personas en todo el mundo. ... more

Download

View PDF

Habilidades Psicosociales Básicas
recommended

the Inter-Agency Standing Committee’s Mental Health and Psychosocial Support Reference Group (2020) C_WHO

Guía para personal de Primera Línea de Respuesta a la COVID-19. Esta Guía básica de habilidades psicosociales es un proyecto del Grupo ... more

Guía para el seguimiento del desarrollo infantil en la práctica pediátrica

Gutson, K.; San Román, N. C., et al Arch Argent Pediatr (2017) C2

El pediatra es el médico de cabecera de los niños pequeños y es el primero en ser consultado por las familias. Los padres esperan que el pediatra no solo sea un experto en atender al niño durant ... more

Download

View PDF

Cómo diagnosticar y tratar la lepra

ILEP (2002) CC

La Guía de Aprendizaje 1 es para todos los profesionales sanitarios que tratan a personas con lepra. Contiene consejos prácticos sobre cómo diagnosticar y dar el tratamiento adecuado para la lepra. Incluye también información básica sobre cóm ... more

Safe Management of Wastes from Health-Care Activities, 2nd. ed.
recommended

World Health Organization WHO (2014) C_WHO

Download

View PDF

Médecins Sans Frontières (MSF) (2022) C2

Esta guía va dirigida a los profesionales de la salud que proporcionan asistencia curativa en dispensarios y hospitales. Hemos intentado responder a las preguntas y problemas con los que se enfrenta el personal sanitario, procurando dar soluciones ... more

Habilidades Psicosociales Básicas recommended

Safe Management of Wastes from Health-Care Activities, 2nd. ed. recommended

Management of Waste from Injection Activities at District Level recommended

Guide to Local Production: WHO-recommended Handrub Formulations recommended

Guía clínica y terapéutica (MSF) recommended

Habilidades Psicosociales Básicas
recommended

Safe Management of Wastes from Health-Care Activities, 2nd. ed.
recommended

Management of Waste from Injection Activities at District Level
recommended

Guide to Local Production: WHO-recommended Handrub Formulations
recommended

Guía clínica y terapéutica (MSF)
recommended